Literature DB >> 14738246

KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome.

H Sato1, M E J Callister, S Mumby, G J Quinlan, K I Welsh, R M duBois, T W Evans.   

Abstract

The acute respiratory distress syndrome (ARDS) is an extreme form of lung injury characterised by disruption to the alveolar epithelium. KL-6 is a mucin-like glycoprotein expressed on type II pneumocytes. Circulating levels of KL-6 have diagnostic and prognostic significance in a number of interstitial lung diseases, and when elevated are thought to indicate disruption of the alveolar epithelial lining. In this study, the authors sought to determine whether plasma KL-6 levels were elevated in patients with ARDS and whether these were associated with aetiology, disease severity, outcome or ventilatory strategy. Plasma samples were collected from 28 patients with ARDS, nine ventilated controls of matched illness severity and 10 healthy individuals. KL-6 concentrations were measured by enzyme-linked immunosorbent assay. Patients with ARDS had higher plasma levels of KL-6 (median 537 U x mL(-1), interquartile range (IQR) 383-1,119), as compared to ventilated controls (median 255 U x mL(-1), IQR 83-338) and normal individuals (median 215 U x mL(-1), IQR 149-307). In patients with ARDS, plasma KL-6 levels were higher in nonsurvivors than survivors, and correlated positively with oxygenation index and negatively with arterial oxygen tension:inspiratory oxygen fraction ratio. There were also significant positive correlations with mean and peak airway pressures. Elevated levels of plasma KL-6 may provide a useful marker for acute respiratory distress syndrome in ventilated patients and have possible prognostic significance. Alveolar epithelial cell damage may be influenced by the nature of mechanical ventilatory support.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14738246     DOI: 10.1183/09031936.03.00070303

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  36 in total

Review 1.  Update on the diagnosis and treatment of Pneumocystis pneumonia.

Authors:  Eva M Carmona; Andrew H Limper
Journal:  Ther Adv Respir Dis       Date:  2010-08-24       Impact factor: 4.031

Review 2.  Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?

Authors:  A R L Medford; A B Millar
Journal:  Thorax       Date:  2006-07       Impact factor: 9.139

Review 3.  Biomarkers in pediatric acute respiratory distress syndrome.

Authors:  Erin F Carlton; Heidi R Flori
Journal:  Ann Transl Med       Date:  2019-10

4.  Obstructive sleep apnea, obesity, and the development of acute respiratory distress syndrome.

Authors:  Lioudmila V Karnatovskaia; Augustine S Lee; S Patrick Bender; Daniel Talmor; Emir Festic
Journal:  J Clin Sleep Med       Date:  2014-06-15       Impact factor: 4.062

5.  Prognostic impact of clinical course-specific mRNA expression profiles in the serum of perioperative patients with esophageal cancer in the ICU: a case control study.

Authors:  Shunsaku Takahashi; Norimasa Miura; Tomomi Harada; ZhongZhi Wang; Xinhui Wang; Hideyuki Tsubokura; Yoshiaki Oshima; Junichi Hasegawa; Yoshimi Inagaki; Goshi Shiota
Journal:  J Transl Med       Date:  2010-10-22       Impact factor: 5.531

6.  Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation.

Authors:  Carolyn S Calfee; Marie M Budev; Michael A Matthay; Gwynne Church; Sandra Brady; Tokujiro Uchida; Akitoshi Ishizaka; Abigail Lara; Justin L Ranes; Malcom M deCamp; Alejandro C Arroliga
Journal:  J Heart Lung Transplant       Date:  2007-07       Impact factor: 10.247

7.  Plasma biomarkers in acute respiratory distress syndrome: a work in progress*.

Authors:  David R Janz; Lorraine B Ware
Journal:  Crit Care Med       Date:  2014-03       Impact factor: 7.598

8.  Circulating KL-6, a biomarker of lung injury, in obstructive sleep apnoea.

Authors:  D J Lederer; S Jelic; R C Basner; A Ishizaka; J Bhattacharya
Journal:  Eur Respir J       Date:  2009-04       Impact factor: 16.671

9.  Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication.

Authors:  Francesco Blasi; Paolo Tarsia; Marco Mantero; Letizia C Morlacchi; Federico Piffer
Journal:  Ther Clin Risk Manag       Date:  2013-02-12       Impact factor: 2.423

10.  Obstructive Sleep Apnea and Subclinical Interstitial Lung Disease in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  John S Kim; Anna J Podolanczuk; Priya Borker; Steven M Kawut; Ganesh Raghu; Joel D Kaufman; Karen D Hinckley Stukovsky; Eric A Hoffman; R Graham Barr; Daniel J Gottlieb; Susan S Redline; David J Lederer
Journal:  Ann Am Thorac Soc       Date:  2017-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.